Molecular Formula | C23H34O5 |
Molar Mass | 390.51 |
Density | 1.13±0.1 g/cm3(Predicted) |
Melting Point | 151-153°C |
Boling Point | 555.0±50.0 °C(Predicted) |
Specific Rotation(α) | D22 +283° (c = 0.48 in acetone) |
Flash Point | 186.5 °C |
Water Solubility | DMSO: 20 mg/mL |
Solubility | DMSO : 25 mg/mL (64.02 mM; Need ultrasonic) |
Vapor Presure | 0Pa at 25℃ |
Appearance | White powder |
Color | white |
Maximum wavelength(λmax) | ['246nm(MeOH)(lit.)'] |
Merck | 14,6164 |
BRN | 1269441 |
pKa | 13.49±0.40(Predicted) |
Storage Condition | 2-8°C |
MDL | MFCD05662341 |
In vitro study | Mevastatin is a cholesterol-lowering agent isolated from Penicillium citinium. At a concentration of 0.01 pg/mL (26 nM), it was able to reduce cholesterol synthesis by 50% compared to the control group. It is structurally similar to HMG, a substituent HMG-CoA the endogenous substrate of reductase. Mevastatin is a prodrug that is activated in vivo by hydrolysis of the lactone ring. The hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase, allowing the reagent to bind with a higher affinity of 10,000 than the natural substrate product. The bicyclic part of mevastatin binds to the active site of coenzyme A. Mevastatin increased eNOS mRNA and protein levels, reduced infarct size, and dose-time-dependently improved neurological deficits. |
In vivo study | At doses of 5 mg/kg and 20 mg/kg, mevastatin reduced serum cholesterol levels 3 hours after oral administration. At a dose of 20 mg/kg, it was able to reduce serum cholesterol levels by approximately 30%. By competitively inhibiting HMG-CoA reductase, Mevastatin is able to lower the cholesterol produced by the liver. Cholesterol levels decreased only after 28 days of treatment and were not associated with a reduction in infarction. Baseline absolute cerebral blood flow was 30% higher after 14 days of high-dose treatment. |
Hazard Symbols | T+ - Very toxic |
Risk Codes | 26/27/28 - Very toxic by inhalation, in contact with skin and if swallowed. |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
WGK Germany | 3 |
RTECS | EK7907100 |
FLUKA BRAND F CODES | 1-8-10 |
HS Code | 29322090 |